Access resources

Provide your email below to receive the latest updates.

Provide your email below to receive the latest updates.

Stay up to date on CLDN18.2

By signing up below, you will receive updates about testing for CLDN18.2 expression in G/GEJ adenocarcinoma. You may also be contacted by an Astellas representative. 

Please provide a valid Email.
You must agree before submitting.
You must agree before submitting.

Successful registration